NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
57 trialsNCT06289673 2026-03-03
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Phase 4 Recruiting
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT06533748 2026-02-12
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06895473 2026-01-30
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT07262957 2025-12-22
PANENCA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4 Recruiting
NCT00136435 2025-10-20
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting
NCT05073172 2024-05-06
StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients
OHSU Knight Cancer Institute
Phase NA Withdrawn
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT01874860 2022-12-01
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
University of Louisville
Phase 2 Completed
NCT03349281 2022-10-20
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
University of Miami
Phase 1 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01451515 2022-06-28
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00006455 2022-05-31
ALCL 99
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT02043587 2022-05-02
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
Phase 2 Terminated
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT04821583 2021-03-29
N-of-1 SLN
Erasmus Medical Center
Phase 3 Unknown
NCT03261336 2021-02-08
Oral Calcitriol With Ketoconazole in CRPC
Inova Health Care Services
Phase 2 Terminated
NCT04621565 2020-11-09
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
Peking Union Medical College Hospital
Phase NA Unknown
NCT02775227 2020-08-24
HYPAR
Helsinki University Central Hospital
Phase 4 Active not recruiting
NCT00460031 2020-07-24
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01036594 2020-06-29
Keto/Dex
University of California, San Francisco
Phase 2 Completed
NCT00853008 2020-04-07
LAL-AR/2003
PETHEMA Foundation
Phase 4 Completed
NCT01540812 2020-03-09
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
PETHEMA Foundation
Completed
NCT01867294 2020-01-09
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
Academic and Community Cancer Research United
Phase 2 Completed
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT00309894 2019-08-05
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
University of California, San Francisco
Phase 2 Completed
NCT00550992 2019-07-30
Interfant06
Dutch Childhood Oncology Group
Phase NA Unknown
NCT00002855 2018-10-31
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002865 2018-08-10
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT01422707 2018-07-19
CBS003
University of Virginia
Phase EARLY_PHASE1 Withdrawn
NCT01422733 2018-07-19
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
University of Virginia
Phase EARLY_PHASE1 Withdrawn
NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT02084134 2018-04-11
Steroid
Washington University School of Medicine
Phase NA Completed
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00899847 2017-10-20
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Stanford University
Phase 2 Completed
NCT02270788 2017-10-03
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00536991 2017-06-14
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00895310 2017-03-30
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
University of California, Davis
Phase 2 Completed
NCT00002494 2016-07-04
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00002760 2016-06-28
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00673127 2015-04-22
KHAD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00176462 2014-06-09
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
Rutgers, The State University of New Jersey
Phase 2 Completed